A retrospective, multicenter study comparing efficacy and safety of Abatacept as a first-line biological agent with that of Abatacept as a second line approach in patients with severe juvenile idiopathic arthritis associated uveitis

Trial Profile

A retrospective, multicenter study comparing efficacy and safety of Abatacept as a first-line biological agent with that of Abatacept as a second line approach in patients with severe juvenile idiopathic arthritis associated uveitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Juvenile rheumatoid arthritis; Uveitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Results published in The Journal of Rheumatology
    • 18 Oct 2016 New trial record
    • 15 Sep 2016 Results published in The Journal of Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top